Company Search:
Advanced Search
Sponsored Links
Generex Biotechnology Corporation Company Snapshot
Generex Biotechnology Corporation operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Generex Biotechnology with three other companies in this sector in the United States: Mannkind Corporation (2012 sales of $35,000.00 of which 100% was Therapeutic Products), TG Therapeutics Inc ($19,048.00 of which 100% was License Revenue), and Histogenics Corp ($26,000.00 of which 100% was Regenerative Medicine).

Sales Analysis. Sales fell dramatically in 2012: Generex Biotechnology reported sales of $28,651.00 for the fiscal year ending July of 2012. This represents a sharp decrease of 90.2% versus 2011, when the company's sales were $291,628.00 .
  Stock Performance Chart for Generex Biotechnology Corporation
  Stock Data: Recent Stock Performance:
  Current Price (1/19/2018): 3.70
(Figures in U.S. Dollars)
1 Week -1.3%   13 Weeks 34.5%  
4 Weeks 41.2%   52 Weeks -17.8%  
Generex Biotechnology Corporation Key Data:
  Ticker: GNBT Country: United States
  Exchanges: FRA OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2012 Sales 28,651
(Year Ending Jan 2013).
Employees: 8
  Currency: U.S. Dollars Market Cap: 3,940,844
  Fiscal Yr Ends: July Shares Outstanding: 1,065,093
  Share Type: Common Closely Held Shares: 397,884
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.